Abstract

Objectives: Evaluate the current evidence on the efficacy of low-dose oral minoxidil (LDOM) for improving hair density and patient-reported quality of life in female pattern hair loss (FPHL). Describe the comprehensive safety profile of LDOM, including the incidence of common adverse events like hypertrichosis and the reassuring findings from recent large-scale cardiovascular safety studies. Integrate the latest safety data into clinical decision-making to confidently prescribe LDOM for FPHL, placing the drug's black box warning in the appropriate clinical context for low-dose use. Introduction: Female pattern hair loss (FPHL) affects 30 million US women. While topical minoxidil is the first-line treatment, its efficacy is limited by poor compliance and variable response. Low-dose oral minoxidil (LDOM) is a promising alternative with practical advantages in adherence. Despite its growing use, no comprehensive systematic evaluation of its safety and efficacy has been conducted. This review synthesises the available clinical evidence to evaluate LDOM for FPHL. Materials / method: This systematic review followed PRISMA guidelines. We searched PubMed, Embase, Web of Science, and Scopus for terms including "LDOM" and "FPHL." Studies were included if they involved women with FPHL treated with LDOM (≤5 mg daily) and reported outcomes on hair density, thickness, or patient satisfaction. Studies on male androgenetic alopecia or topical-only treatments were excluded. Primary outcomes were changes in hair density and thickness; secondary outcomes were physician and patient assessments. Results: Ten studies (n=593) were included. Women with FPHL treated with LDOM (0.25-2 mg/day) showed hair density increases of 12-38% and significant quality of life improvements (p<0.01). One study reported clinical improvement in 79.7% of patients. LDOM demonstrated superiority over topical minoxidil in a comparative study (12% vs 7.2% density increase). Adverse events were generally mild, most commonly hypertrichosis, peripheral edema, postural hypotension, and headache. Conclusion: Low-dose oral minoxidil is an effective treatment for female pattern hair loss, demonstrating consistent improvements in hair density and patient satisfaction. The safety profile at the low doses reviewed appears favorable, with most adverse events being mild. Nevertheless, it is crucial for clinicians to recognize that oral minoxidil carries a black box warning for serious cardiovascular events, which underscores the importance of careful patient screening. Further large-scale trials are needed to confirm these safety findings and establish optimal dosing protocols.